Merck and Moderna say intismeran autogene plus Keytruda met its primary endpoint in a Phase 3 melanoma trial. What the topline result does and does not show.
A Custom mRNA Therapy Built from Each Patient’s Tumor Improved Melanoma Recurrence-Free Survival in a Phase 3 Trial
by | Aug 20, 2026 | Uncategorized | 0 comments
Recent Comments